Moleculera Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
Moleculera Biosciences, Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AUTOIMMUNE BRAIN PANEL and MOLECULERA BIOSCIENCES. The owner is based in Oklahoma City, OK.
755 Research Parkway, Suite 410
Oklahoma City, OK 73104
Showing of trademarks Trademarks
Trademark Classifications
Moleculera Biosciences, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Moleculera Biosciences, Inc. have?
Moleculera Biosciences, Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Moleculera Biosciences, Inc. file in?
Moleculera Biosciences, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Moleculera Biosciences, Inc.'s most well-known trademarks?
Moleculera Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as AUTOIMMUNE BRAIN PANEL and MOLECULERA BIOSCIENCES. These are among 2 currently registered trademarks in the portfolio.
What is Moleculera Biosciences, Inc.'s trademark registration success rate?
Moleculera Biosciences, Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.